Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 3
2021 4
2022 6
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. BMC Cancer. 2024 Apr 17;24(1):487. doi: 10.1186/s12885-024-12249-y. BMC Cancer. 2024. PMID: 38632499 Free PMC article. No abstract available.
Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort.
Ceccarelli F, Natalucci F, Picciariello L, Cirillo A, Olivieri G, Veroli M, Pisegna S, Ciancarella C, Gelibter A, Picone V, Santini D, Botticelli A, Conti F. Ceccarelli F, et al. Among authors: cirillo a. Clin Exp Med. 2024 Apr 10;24(1):72. doi: 10.1007/s10238-024-01317-z. Clin Exp Med. 2024. PMID: 38598028 Free PMC article.
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. BMC Cancer. 2024 Apr 8;24(1):430. doi: 10.1186/s12885-024-12155-3. BMC Cancer. 2024. PMID: 38589857 Free PMC article.
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Nelli F, Fabbri A, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Berrios JRG, Scagnoli S, Pisegna S, Cirillo A, Panichi V, Massari A, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: cirillo a. Front Oncol. 2023 Nov 7;13:1280416. doi: 10.3389/fonc.2023.1280416. eCollection 2023. Front Oncol. 2023. PMID: 38023235 Free PMC article.
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey.
Cerbelli B, Cirillo A, Pomati G, Pernazza A, Ascione A, Pisegna S, Pisano A, Leopizzi M, Pignataro MG, Costarelli L, Mulè A, Vecchione A, Catalano P, Coppola L, Perrone G, Perracchio L, Anemona L, Mastracchio A, Nardi S, Reitano R, Massari A, Grillo LR, Liberati F, Della Rocca C, Marchetti P, Botticelli A, D'Amati G. Cerbelli B, et al. Among authors: cirillo a. Tumori. 2024 Feb;110(1):44-48. doi: 10.1177/03008916231196781. Epub 2023 Sep 19. Tumori. 2024. PMID: 37726962
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Botticelli A, Cirillo A, Pomati G, Cortesi E, Rossi E, Schinzari G, Tortora G, Tomao S, Fiscon G, Farina L, Scagnoli S, Pisegna S, Ciurluini F, Chiavassa A, Amirhassankhani S, Ceccarelli F, Conti F, Di Filippo A, Zizzari IG, Napoletano C, Rughetti A, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: cirillo a. Cancer Immunol Immunother. 2023 Jul;72(7):2217-2231. doi: 10.1007/s00262-023-03384-9. Epub 2023 Mar 3. Cancer Immunol Immunother. 2023. PMID: 36869232 Free PMC article.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A, Rossi E, Schinzari G, Tortora G, Di Pietro FR, Cerbelli B, Di Filippo A, Amirhassankhani S, Scala A, Zizzari IG, Cortesi E, Tomao S, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: cirillo a. Front Immunol. 2022 Nov 3;13:974087. doi: 10.3389/fimmu.2022.974087. eCollection 2022. Front Immunol. 2022. PMID: 36405727 Free PMC article.
Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile.
Mezi S, Pomati G, Zizzari IG, Di Filippo A, Cerbelli B, Cirillo A, Fiscon G, Amirhassankhani S, Valentini V, De Vincentiis M, Corsi A, Di Gioia C, Tombolini V, Della Rocca C, Polimeni A, Nuti M, Marchetti P, Botticelli A. Mezi S, et al. Among authors: cirillo a. Biomedicines. 2022 Oct 28;10(11):2732. doi: 10.3390/biomedicines10112732. Biomedicines. 2022. PMID: 36359251 Free PMC article.
21 results